Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 7 – 11, 2024. The management team will also participate in one-on-one investor meetings.
Related news for (VERA)
- Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
- Stocks to Watch into the Closing Bell – June 2, 2025
- Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
- Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results